Biora Therapeutics Return on Equity

Biora Therapeutics (BIOR) currently reports a ROE of 29.58%. That is above the Healthcare sector average of 29.39%. Use the charts on this page to explore Biora Therapeutics's ROE history and peer comparisons.

Biora Therapeutics's ROE of 29.58% is higher than the Healthcare sector average of 29.39%. That is roughly 0.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biora Therapeutics's current 29.58% should be judged against Healthcare norms (sector average: 29.39%) and against BIOR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 29.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Biora Therapeutics, and consider following BIOR for alerts when major investors trade the stock.

Biora Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 29.58% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIOR with unrelated industries.